{"id":24847,"date":"2021-11-02T09:27:37","date_gmt":"2021-11-02T09:27:37","guid":{"rendered":"https:\/\/touchophthalmology.com\/?post_type=media_gallery&p=24847"},"modified":"2021-11-02T09:27:37","modified_gmt":"2021-11-02T09:27:37","slug":"anja-tuulonen-escrs-2021-cost-effectiveness-of-the-big-four-eye-diseases","status":"publish","type":"media_gallery","link":"https:\/\/touchophthalmology.com\/cataract-surgery\/conference-hub\/anja-tuulonen-escrs-2021-cost-effectiveness-of-the-big-four-eye-diseases\/","title":{"rendered":"Anja Tuulonen, ESCRS 2021: Cost-effectiveness of the \u2018Big Four\u2019 Eye Diseases"},"content":{"rendered":"

It was a pleasure to speak with Anja Tuulonen (Tays Eye Centre, Tampere University Hospital, Tampere, Finland), who talked us through her presentation on the \u2018big four\u2019 eye diseases, and the real-life cost-effectiveness of interventions to treat them.<\/p>\n

    \n
  1. What proportion of eye diseases are accounted for by the \u2018big four\u2019? (00:20)<\/li>\n
  2. What are the major challenges of resource allocation within ophthalmology? (00:52)<\/li>\n
  3. Why is it so important to measure real-life effectiveness of interventions in ophthalmology? (01:59)<\/li>\n
  4. Could you give us a brief overview of the model developed in Finland to optimize the effectiveness, sustainability and outcomes of eyecare services? (03:19)<\/li>\n
  5. What are the strengths of the model and how do you hope this approach will be adopted? (04:59)<\/li>\n<\/ol>\n

    Speaker Disclosure: <\/b>Anja Tuulonen has no financial or non-financial relationships or activities to declare in relation to this interview.<\/p>\n

    Support:<\/b> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.<\/p>\n

    Filmed in coverage of ESCRS 2021.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

    It was a pleasure to speak with Anja Tuulonen (Tays Eye Centre, Tampere University Hospital, Tampere, Finland), who talked us through her presentation on the \u2018big four\u2019 eye diseases, and the real-life cost-effectiveness of interventions to treat them. What proportion of eye diseases are accounted for by the \u2018big four\u2019? (00:20) What are the major […]<\/p>\n","protected":false},"featured_media":24848,"template":"","class_list":["post-24847","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-cataract-surgery","video_categories-escrs-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/24847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":1,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/24847\/revisions"}],"predecessor-version":[{"id":24849,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media_gallery\/24847\/revisions\/24849"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media\/24848"}],"wp:attachment":[{"href":"https:\/\/touchophthalmology.com\/wp-json\/wp\/v2\/media?parent=24847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}